STAT3 and neoplasm: Herein, we developed biostable iDR-NC/neoantigen complexes as nanovaccines that incorporated CpG and Stat3 shRNA, as well as tumor-specific neoantigens for efficient co-delivery and immunomodulation in cancer immunotherapy.